David H. Johnson

34.4k citations

242 papers · 26.2k indexed · 12 hit papers · h-index 61

Impact in

Pulmonary and Respiratory Medicine top 0.01%
- Lung Cancer Treatments and Mutations
- Lung Cancer Diagnosis and Treatment
- Gastric Cancer Management and Outcomes
Oncology top 0.02%
- Lung Cancer Research Studies
- Colorectal Cancer Treatments and Studies
- HER2/EGFR in Cancer Research

Papers in

Pulmonary and Respiratory Medicine 160
- Lung Cancer Treatments and Mutations 126
- Lung Cancer Diagnosis and Treatment 82
- Respiratory Support and Mechanisms 10
Oncology 106
- Lung Cancer Research Studies 62
- Colorectal Cancer Treatments and Studies 20
- HER2/EGFR in Cancer Research 13
- Cancer Treatment and Pharmacology 13

Co-authors: Joan H. Schiller Corey J. Langer Alan Sandler Chandra P. Belani James E. Krook David Harrington Junming Zhu Roy S. Herbst
Journals: Journal of Clinical Oncology (65 papers)Lung Cancer (32 papers)Journal of Thoracic Oncology (13 papers)Cancer (9 papers)Clinical Cancer Research (8 papers)
Partner nations: United States Canada United Kingdom

In The Last Decade

David H. Johnson

237 papers receiving 25.4k citations

Hit Papers

12 papers align trajectories log scale

American Society of Clinical Oncology Provisional Clinical Opinion: Epidermal Growth Factor Receptor (EGFR) Mutation Testing for Patients With Advanced Non–Small-Cell Lung Cancer Considering First-Line EGFR Tyrosine Kinase Inhibitor Therapy 2011 · 399 citations

What are hit papers?

Hit papers significantly outperform the citation benchmark for their cohort. A paper qualifies if any of the following hold:

it has ≥500 total citations;
it reaches ≥1.5× the top-1% citation threshold for papers in the same subfield and year (the threshold is the minimum needed to enter the top 1%, not the average within it);
it reaches the top citation threshold in at least one of its specific research topics.

2011 Journal of Clinical Oncology
2010 The Lancet
2009 Journal of Clinical Oncology
2009 The Lancet
2005 Journal of Clinical Oncology
2005 Journal of Clinical Oncology
2005 Journal of Clinical Oncology
2004 Journal of Clinical Oncology
2004 Journal of Clinical Oncology
2004 Journal of Clinical Oncology
2003 Journal of Clinical Oncology
2002 New England Journal of Medicine

Peers

Countries citing papers authored by David H. Johnson

Since Specialization

Citations

This map shows the geographic impact of David H. Johnson's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by David H. Johnson with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites David H. Johnson more than expected).

Fields of papers citing papers by David H. Johnson

Since Specialization

Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by David H. Johnson. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by David H. Johnson. The network helps show where David H. Johnson may publish in the future.

Co-authorship network

The 25 scholars most cited alongside David H. Johnson, linked wherever they have co-authored with each other. Click a name or a connecting line to browse the papers they share.

Border = papers with David H. Johnson Line = papers co-authored together David H. Johnson links everyone, so they are left out of the graph.

All Works

Sort: Min cites: Since: Top N: Style:

20 of 20 papers shown

#	Work
1	Assessing Barriers and Facilitators to Lung Cancer Screening: Initial Findings from a Patient Navigation Intervention Population Health Management ·Simon J. Craddock Lee, Jessica L. Lee, Hong Zhu, Livia Pescarollo, Pengzhen Sheng, Heidi Hamann, Sheena Bhalla, 胡堂野村, 晃良吉田, David H. Johnson, Noel Santini, Andreas Knaus, David E. Gerber	2023	6
2	Prevalence And Impact of Medical Comorbidities in A Real‐World Lung Cancer Screening Population Clinical Lung Cancer ·Nurwanto Fariadi, Hong Zhu, Sarah Williams, Heidi Hamann, 晃良吉田, 多胡賢一, Noel Santini, Travis Browning, Mitch Lieberth, 浦濱善倫, N. Minh, David S. Balis, P.A.J.M.M. COCK, Ellen Kitchell, David H. Johnson, Simon J. Craddock Lee, David E. Gerber	2022	12
3	Validation of the 12-gene Predictive Signature for Adjuvant Chemotherapy Response in Lung Cancer Clinical Cancer Research ·Yang Xie, Wei Lü, Shidan Wang, Ximing Tang, Hao Tang, Yunyun Zhou, César A. Moran, Carmen Behrens, Jack A. Roth, Qinghua Zhou, David H. Johnson, Stephen G. Swisher, John V. Heymach, Vassiliki A. Papadimitrakopoulou, Guanghua Xiao, John D. Minna, Ignacio I. Wistuba	2018	13
4	American Society of Clinical Oncology Clinical Practice Guideline Update on Chemotherapy for Stage IV Non–Small-Cell Lung Cancer Journal of Clinical Oncology ·Christopher G. Azzoli, Sherman Baker, Sarah Temin, William Pao, Timothy Aliff, Julie R. Brahmer, David H. Johnson, V. I. Nozadrin, Gregory A. Masters, Daniel T. Milton, Luke T. Nordquist, David G. Pfister, Steven Piantadosi, Joan H. Schiller, R. Smith, Thomas J. Smith, John R. Strawn, David Trent, Giuseppe Giaccone Hit paper breakdown →	2009	752
5	Cell Adhesion Molecules, Vascular Endothelial Growth Factor, and Basic Fibroblast Growth Factor in Patients with Non–Small Cell Lung Cancer Treated with Chemotherapy with or without Bevacizumab—an Eastern Cooperative Oncology Group Study Clinical Cancer Research ·Afshin Dowlati, Robert J. Gray, Alan B. Sandler, Joan H. Schiller, David H. Johnson	2008	208
6	PD3-3-5: Outcomes for elderly advanced stage non-small cell lung cancer (NSCLC) patients (pts) treated with bevacizumab (B) in combination with carboplatin (C) and paclitaxel (P): Analysis of Eastern Cooperative Oncology Group (ECOG) 4599 study Journal of Thoracic Oncology ·Suresh S. Ramalingam, Suzanne E. Dahlberg, Corey J. Langer, Robert J. Gray, Chandra P. Belani, Julie R. Brahmer, Alan Sandler, Joan H. Schiller, David H. Johnson	2007	1
7	B2-03: Supportive care and chemotherapy (CT) versus supportive care alone in advanced non-small cell lung cancer (NSCLC): A meta-analysis using individual patient data (IPD) from randomised controlled trials (RCTs) Journal of Thoracic Oncology ·Sarah Burdett, David H. Johnson, Lesley Stewart, Jayne F. Tierney, C. Le Péchoux	2007	7
8	Thioredoxin-1 Modulates Transcription of Cyclooxygenase-2 via Hypoxia-Inducible Factor-1α in Non–Small Cell Lung Cancer Cancer Research ·Ildiko Csiki, Kiyoshi Yanagisawa, Nobuhiro Haruki, Sorena Nadaf, Jason D. Morrow, David H. Johnson, David P. Carbone	2006	79
9	EGFR Dinucleotide Repeat Polymorphism as a Prognostic Indicator in Non-small Cell Lung Cancer Journal of Thoracic Oncology ·Sarita Dubey, Patricia Stephenson, Donna E. Levy, Judith Miller, Steven M. Keller, Joan H. Schiller, David H. Johnson, Jill Kolesar	2006	32
10	Post-operative radiotherapy (PORT) or chemoradiotherapy (CPORT) following resection of stages II and IIIA non-small cell lung cancer (NSCLC) does not increase the expected risk of death from intercurrent disease (DID) in Eastern Cooperative Oncology Group (ECOG) trial E3590 Lung Cancer ·Heather A. Wakelee, Patricia Stephenson, Steven M. Keller, Henry Wagner, Arnold Herskovic, Ritsuko Komaki, Randolph S. Marks, Michael C. Perry, Robert B. Livingston, David H. Johnson	2005	42
11	Efficacy and safety of the monoclonal anti-tumor necrosis factor antibody F(ab′)2 fragment afelimomab in patients with severe sepsis and elevated interleukin-6 levels* Critical Care Medicine ·Edward A. Panacek, John C. Marshall, Timothy E. Albertson, David H. Johnson, Steven B. Johnson, Rodger D. MacArthur, Mark Miller, William Barchuk, Steven Fischkoff, Martin Kaul, Leah Teoh, 仁宏岡本, Chilankamol Sunny, Stanley Lemeshow, 純一太田, Christopher J. Doig	2004	267
12	Increased matrix metalloproteinase activity after canine cardiopulmonary bypass is suppressed by a nitric oxide scavenger Journal of Thoracic and Cardiovascular Surgery ·Irvin Mayers, Thomas S. Hurst, Anna Radomski, David H. Johnson, Simon P. Fricker, Gary Bridger, Beth R. Cameron, Marilyn C. Darkes, Marek W. Radomski	2003	19
13	EMS Adherence to a Pre-hospital Cervical Spine Clearance Protocol SHILAP Revista de lepidopterología ·David H. Johnson, Mark I. Langdorf, Kenneth G. Miller, R J Sebastian	2001	3
14	Induction chemoradiation and surgical resection for non–small cell lung carcinomas of the superior sulcus: Initial results of Southwest Oncology Group Trial 9416 (Intergroup Trial 0160) Journal of Thoracic and Cardiovascular Surgery ·Valerie W. Rusch, Dorothy J. Giroux, Michael Kraut, John Crowley, Mark B. Hazuka, David H. Johnson, Melvyn Goldberg, Frank C. Detterbeck, Frances A. Shepherd, Ronald L. Burkes, Timothy Winton, Claude Deschamps, Robert B. Livingston, David Gandara	2001	187
15	Induction chemotherapy increases perioperative complications in patients undergoing resection for non–small cell lung cancer The Annals of Thoracic Surgery ·John R. Roberts, 麦兆章, Russell F. DeVore, David P. Carbone, Hak Choy, David H. Johnson	2001	91
16	Induction paclitaxel/carboplatin in early stage non-small cell lung cancer Seminars in Oncology ·Katherine M.W. Pisters, Mark G. Kris, Paul A. Bunn, David H. Johnson, John C. Ruckdeschel, John J. Crowley, Robert J. Ginsberg	1997	2
17	Postoperative Physical Therapy After Coronary Artery Bypass Surgery American Journal of Respiratory and Critical Care Medicine ·David H. Johnson, Popescu Veronica, Teresa To, Tom Hurst, Charles Elliott Hultquist, Irene Gulka, Dorothy Thomson, Katherine East, Masato Ninomiya, Irvin Mayers	1995	44
18	Cisplatin plus doxorubicin plus cyclophosphamide in metastatic or recurrent thymoma: final results of an intergroup trial. The Eastern Cooperative Oncology Group, Southwest Oncology Group, and Southeastern Cancer Study Group. Journal of Clinical Oncology ·Patrick J. Loehrer, KyungMann Kim, Seena C. Aisner, Robert B. Livingston, Lawrence Einhorn, David H. Johnson, Rob Blum	1994	218
19	Non-Hodgkin's lymphoma of the gastrointestinal tract: an analysis of clinical and pathologic features affecting outcome. Journal of Clinical Oncology ·Alan F. List, J P Greer, Henry Normand, Richard S. Stein, David H. Johnson, Vernon Reynolds, Filippo Greco, John M. Flexner, Kenneth R. Hande	1988	72
20	Estimates for Nonanalytic Cusp Forms Proceedings of the American Mathematical Society ·David H. Johnson	1984	1

About David H. Johnson

David H. Johnson is a scholar working on Pulmonary and Respiratory Medicine, Oncology, Hepatology, Neurology and Cancer Research, having authored 242 papers that have together received 26.2k indexed citations. Recurring topics across this work include Lung Cancer Treatments and Mutations (126 papers), Lung Cancer Diagnosis and Treatment (82 papers), Lung Cancer Research Studies (62 papers), Colorectal Cancer Treatments and Studies (20 papers), HER2/EGFR in Cancer Research (13 papers), Hepatocellular Carcinoma Treatment and Prognosis (13 papers), Cancer Treatment and Pharmacology (13 papers) and Respiratory Support and Mechanisms (10 papers). The work is most often cited by research in Pulmonary and Respiratory Medicine (18.4k citations), Oncology (15.1k citations), Cancer Research (3.3k citations), Otorhinolaryngology (475 citations) and Hepatology (838 citations). David H. Johnson has collaborated with scholars based in United States, Canada and United Kingdom. Frequent co-authors include Joan H. Schiller, Corey J. Langer, Alan Sandler, Chandra P. Belani, James E. Krook, David Harrington, Junming Zhu, Roy S. Herbst, Vincent A. Miller and Robert B. Livingston. Their work appears in journals such as Journal of Clinical Oncology, Lung Cancer, Journal of Thoracic Oncology, Cancer and Clinical Cancer Research.

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact